1. Climb Bio announces participation in key healthcare investor conferences. 2. Conferences include Cantor, Baird, Morgan Stanley, and Stifel. 3. CLYM116, in development for IgA nephropathy, promotes investor interest. 4. Company showcases pipeline of therapeutics targeting immune-mediated diseases.
Upcoming investor conferences may attract attention and investment interest for CLYM. Similar events in biotech often lead to positive market reactions when potential is highlighted.
The announcement about investor conferences is likely to enhance visibility and foster investor discussions about CLYM’s potential, critical for a clinical-stage company.
Investor interest could increase around conference dates; immediate buying opportunities might arise. Historical examples indicate spikes in stock price following successful conference presentations.
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below.
Cantor Global Healthcare Conference
Location: New York, NY
Format: Fireside chat and one-on-one investor meetings
Date: Friday, September 5, 2025
Time: 10:55 a.m. ET
Baird Global Healthcare Conference
Location: New York, NY
Format: Fireside chat and one-on-one investor meetings
Date: Tuesday, September 9, 2025
Time: 4:20 PM p.m. ET
Morgan Stanley Annual Global Healthcare Conference
Location: New York, NY
Format: One-on-one meetings only
Date: Wednesday, September 10, 2025
Stifel Virtual Immunology and Inflammation Forum
Location: Virtual
Format: Presentation and one-on-one investor meetings
Date: Tuesday, September 16, 2025
Time: 10:30 a.m. ET
The live webcasts will be accessible via the "Investors and News" section of the Climb Bio website: https://ir.climbbio.com/. Webcast replays will be available on the Climb Bio website beginning approximately two hours after each webcast event and will be archived for at least 30 days.
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.
Investors and Media
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
